James Priour - 06 Jul 2021 Form 4 Insider Report for Zymeworks Inc.

Reporting relationship: Chief Commercial Officer
Issuer ticker: N/A
Reported as of: 06 Jul 2021
Net transaction value: +$15,040
SEC form: 4
Accepted by SEC: 08 Jul 2021, 20:00:21 UTC
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

James Priour filed Form 4 for Zymeworks Inc. on 08 Jul 2021.

Key facts

This page summarizes James Priour's Form 4 filing for Zymeworks Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Jul 2021, 20:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$15,040.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYME transaction

Common Shares

Award

Transaction value: $15,040
Shares: +510
Change %: +25%
Price: $29.49^*
Shares after: 2,513
Date: 06 Jul 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2021 through June 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2021.